Omnicell, Inc. (OMCL) Stock | OMCL Stock Price & Analysis

Feed

OMCL

Omnicell, Inc. OMCL · NASDAQ

$37.75 +1.75% (+$0.65)

Summary

51 / 100 · Bulios Score

Valuation 62Growth 31Profitability 51Quality 18Debt 97Stability 57

What speaks for it

It holds more cash than debt: $292.2M against $200.0M.
It bought back its own shares for $77.6M in the last fiscal year, 4.6% of its market value.
Out of every 100 USD of revenue, 11 USD is left as free cash.

What to watch

Earnings per share fell by 28% a year over the last 3 years.
The share price is above the Bulios Fair Price.
Out of every 100 USD of revenue, only 3.1 USD is left as net profit.
It earns only 2.4 USD a year on every 100 USD of invested capital.

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Score in detail

Is it expensive?

Looks expensive

Bulios Fair Price

Current price $37.75

P/E today 43.2 90% lower

5-year average P/E 427.2

P/E today 43.2

Medical - Healthcare Information Services industry median

Unlock fair price

Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?

Today you pay 43.2 USD for 1 USD of yearly profit. Over the last five years it was 427.2 USD on average.

Valuation in detail

Is it growing?

It is shrinking

Revenue (USD)

1.1B

1.3B

1.1B

1.2B

1.3B

2021202220232024202520262027

Diluted EPS (USD)

$1.62

$0.12

-$0.45

$0.27

$0.04

$2.27

$2.06

2021202220232024202520262027

Analyst estimate

Revenue grew by 5.8% a year over 5 years. Over the last 3 years it fell by 2.9% a year. For the next fiscal year analysts expect revenue to grow by 4.4%. Earnings per share fell by 28% a year over the last 3 years.

Growth in detail

Does it make money?

Reasonably

Where 100 USD of revenue goes

Cost of sales 55 USD
Research and development 7.1 USD
Sales and administration 33 USD
Taxes and other 1.6 USD
Net profit 3.1 USD

Net profit, industry median (Medical - Healthcare Information Services) 4.7 USD

Out of every 100 USD of revenue, 3.1 USD is left as net profit.

Profitability in detail

Is it financially healthy?

Yes

Cash and short-term investments $307.0M

Debt $200.0M

Free cash flow over 12 months $141.4M

Repaying all its debt would take 1.4 years of free cash flow. It holds more cash than debt.

Financial health in detail

Does it pay a dividend?

It pays no dividend.

Dividends in detail

What do analysts expect?

Neutral

Buy 9
Hold 10
Sell 0

Today's price within the analysts' price targets

Today's price $37.75 Average target $56.67

$37.75 $65

The average target of $56.67 is 50% above today's price. 47% of the analysts recommend buying.

Analysts in detail

What does it earn on?

Fiscal year 2025

By product

Connected Devices, Software Licenses, And Other 48%
Technical Services 22%
Hardware And Software 22%
Consumables 8.5%

By region

UNITED STATES 90%
Non-US 10%

Connected Devices, Software Licenses, And Other brings in 48% of revenue. Hardware And Software grew fastest, by 23% a year.

Segments in detail